Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs

Suzhou, China, May 12, 2025 –Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological，an innovator in novel cancer therapeutics. Porton Advanced will provide end-to-end CDMO services for Hualong's Multi-Activated T Cell (MATC) therapy, from process optimization to regulatory submission, accelerating its development progress.

Hualong Biological 's research team has established a strong clinical foundation for its MATC platform through multiple investigator-initiated trials（IITs）, demonstrating significant therapeutic benefits across various solid tumor indications. Porton Advanced will leverage its industry-leading process development platforms, GMP manufacturing capabilities, and proven regulatory expertise to optimize the MATC therapy's CMC strategy and facilitate its transition from research to clinical development.

Mingguang Huang, Chairman of Hualong Biological, commented: “We are delighted to partner with Porton Advanced. Their comprehensive CDMO technical expertise and regulatory experience in cell therapy will significantly enhance our MATC program's development efficiency and IND preparation timeline. Together, we’re committed to advancing this innovative therapy into clinical trials to benefit patients worldwide.”

Andrew Chen, CFO of Porton Advanced, stated: “Collaborating with Hualong Biological marks a strategic expansion of our CDMO services in cell therapy. We are honored to provide regulatory-compliant, high-quality MATC CMC services to support their IND application. Porton Advanced is committed to supporting partners through our integrated technology platform and regulatory experience to bring cutting-edge therapies to patients faster.”

About Hualong Biological

Founded in 2012, Henan Hualong Biological is a national high-tech enterprise in China specializing in cell technology development and applications. Aligned with its strategic vision of integrating cell storage, research, therapeutic development, and clinical applications, Hualong Biological primarily focuses on cell banking, cell therapy development, and related cell technology services.

About Porton Advanced

Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.